Avrobio Inc (AVRO) Receives a Rating Update from a Top Analyst

By Carrie Williams

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Avrobio Inc (AVROResearch Report) yesterday. The company’s shares closed yesterday at $19.16.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3% and a 52.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Avrobio Inc is a Moderate Buy with an average price target of $40.

See today’s analyst top recommended stocks >>

Based on Avrobio Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $16.02 million. In comparison, last year the company had a GAAP net loss of $8.24 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. The company was founded by Jeffrey Medin and Christopher Paige in 2015 and is headquartered in Cambridge, MA.